Philip D. Greenberg

32.5k total citations · 11 hit papers
246 papers, 22.5k citations indexed

About

Philip D. Greenberg is a scholar working on Immunology, Oncology and Epidemiology. According to data from OpenAlex, Philip D. Greenberg has authored 246 papers receiving a total of 22.5k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Immunology, 137 papers in Oncology and 43 papers in Epidemiology. Recurrent topics in Philip D. Greenberg's work include CAR-T cell therapy research (115 papers), Immune Cell Function and Interaction (105 papers) and Immunotherapy and Immune Responses (101 papers). Philip D. Greenberg is often cited by papers focused on CAR-T cell therapy research (115 papers), Immune Cell Function and Interaction (105 papers) and Immunotherapy and Immune Responses (101 papers). Philip D. Greenberg collaborates with scholars based in United States, South Africa and Germany. Philip D. Greenberg's co-authors include Stanley R. Riddell, Cassian Yee, Joseph N. Blattman, M. Jean Gilbert, Ingunn M. Stromnes, Martin A. Cheever, Andrea Schietinger, William Ho, Brad H. Nelson and E. Donnall Thomas and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Philip D. Greenberg

235 papers receiving 22.1k citations

Hit Papers

Reconstitution of Cellula... 1991 2026 2002 2014 1995 1992 2002 1999 2006 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
    1995 1.5k citations Philip D. Greenberg, Stanley R. Riddell et al. profile →
  2. Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
    1992 1.0k citations Stanley R. Riddell, Philip D. Greenberg et al. Science profile →
  3. Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cells
    2002 941 citations Cassian Yee, Stanley R. Riddell et al. Proceedings of the National Academy of Sciences profile →
  4. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
    1999 919 citations Cassian Yee, Philip D. Greenberg et al. profile →
  5. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development
    2006 640 citations Marc A. Gavin, Troy R. Torgerson et al. Proceedings of the National Academy of Sciences profile →
  6. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    2008 573 citations Brian G. Till, Michael C. Jensen et al. Blood profile →
  7. Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells
    1991 511 citations Philip D. Greenberg profile →
  8. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
    2017 509 citations Kristin G. Anderson, Ingunn M. Stromnes et al. Cancer Cell profile →
  9. Tolerance and exhaustion: defining mechanisms of T cell dysfunction
    2013 503 citations Andrea Schietinger, Philip D. Greenberg profile →
  10. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
    2016 484 citations Andrea Schietinger, Edison Y. Chiu et al. profile →
  11. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
    2012 431 citations Brian G. Till, Michael C. Jensen et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip D. Greenberg United States 74 15.2k 11.4k 4.5k 4.3k 3.6k 246 22.5k
Gerold Schuler Germany 84 25.1k 1.6× 7.7k 0.7× 7.8k 1.7× 2.4k 0.6× 2.0k 0.5× 355 33.0k
James L. Riley United States 67 12.3k 0.8× 9.7k 0.8× 4.1k 0.9× 1.4k 0.3× 2.5k 0.7× 149 18.8k
Nina Bhardwaj United States 83 20.6k 1.4× 7.7k 0.7× 8.2k 1.8× 2.5k 0.6× 1.4k 0.4× 332 27.6k
Cornelis J.M. Melief Netherlands 75 17.7k 1.2× 8.8k 0.8× 7.0k 1.6× 3.8k 0.9× 1.7k 0.5× 233 22.4k
Pedro Romero Switzerland 85 19.9k 1.3× 9.8k 0.9× 8.6k 1.9× 1.9k 0.4× 1.5k 0.4× 343 26.7k
Stanley R. Riddell United States 98 16.1k 1.1× 20.5k 1.8× 7.8k 1.7× 6.5k 1.5× 7.1k 2.0× 303 34.0k
Jan W. Drijfhout Netherlands 77 11.4k 0.7× 3.7k 0.3× 6.8k 1.5× 4.2k 1.0× 2.6k 0.7× 319 21.2k
Douglas T. Fearon United States 76 15.2k 1.0× 6.6k 0.6× 5.4k 1.2× 2.2k 0.5× 1.1k 0.3× 178 24.5k
Eli Gilboa United States 76 10.5k 0.7× 6.0k 0.5× 11.5k 2.6× 1.1k 0.2× 5.0k 1.4× 183 20.0k
Esteban Celis United States 63 13.5k 0.9× 8.6k 0.8× 5.4k 1.2× 2.1k 0.5× 918 0.3× 205 18.7k

Countries citing papers authored by Philip D. Greenberg

Since Specialization
Citations

This map shows the geographic impact of Philip D. Greenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip D. Greenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip D. Greenberg more than expected).

Fields of papers citing papers by Philip D. Greenberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip D. Greenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip D. Greenberg. The network helps show where Philip D. Greenberg may publish in the future.

Co-authorship network of co-authors of Philip D. Greenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Philip D. Greenberg. A scholar is included among the top collaborators of Philip D. Greenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip D. Greenberg. Philip D. Greenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alencar, Gabriel F., Yapeng Su, Valentin Voillet, et al.. (2025). Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer. Proceedings of the National Academy of Sciences. 122(39). e2419888122–e2419888122.
2.
Qiu, Yajing, Yapeng Su, Hongcheng Cheng, et al.. (2024). Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. Cancer Cell. 43(1). 103–121.e8. 20 indexed citations
3.
Anderson, Kenneth C., Lewis C. Cantley, Riccardo Dalla‐Favera, et al.. (2022). The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Discovery. 12(11). 2475–2481.
4.
Anderson, Kristin G., et al.. (2022). Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. Journal for ImmunoTherapy of Cancer. 10(3). e003959–e003959. 17 indexed citations
5.
Anderson, Kristin G., Valentin Voillet, Breanna M. Bates, et al.. (2019). Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Cancer Immunology Research. 7(9). 1412–1425. 27 indexed citations
6.
Stromnes, Ingunn M., Adam L. Burrack, Ayaka Hulbert, et al.. (2019). Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. Cancer Immunology Research. 7(6). 977–989. 52 indexed citations
7.
Stromnes, Ingunn M., Ayaka Hulbert, Robert H. Pierce, Philip D. Greenberg, & Sunil R. Hingorani. (2017). T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunology Research. 5(11). 978–991. 148 indexed citations
8.
Stromnes, Ingunn M., Thomas M. Schmitt, Ayaka Hulbert, et al.. (2015). T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell. 28(5). 638–652. 151 indexed citations
9.
Chapuis, Aude G., Gunnar B. Ragnarsson, Hieu Nguyen, et al.. (2013). Transferred WT1-Reactive CD8 + T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients. Science Translational Medicine. 5(174). 174ra27–174ra27. 242 indexed citations
10.
Berrien-Elliott, Melissa M., Stephanie R. Jackson, Hideo Yagita∥, et al.. (2012). Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance. Cancer Research. 73(2). 605–616. 38 indexed citations
11.
Schietinger, Andrea, Jeffrey J. Delrow, Ryan Basom, Joseph N. Blattman, & Philip D. Greenberg. (2012). Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State. Science. 335(6069). 723–727. 126 indexed citations
12.
Till, Brian G., Michael C. Jensen, Jinjuan Wang, et al.. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 119(17). 3940–3950. 431 indexed citations breakdown →
13.
Kuball, Jürgen, Beate Hauptrock, Ralf-Holger Voss, et al.. (2009). Increasing functional avidity of TCR-redirected T cells by removing defined N -glycosylation sites in the TCR constant domain. The Journal of Experimental Medicine. 206(2). 463–475. 111 indexed citations
14.
Gavin, Marc A., Troy R. Torgerson, Evan Houston, et al.. (2006). Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proceedings of the National Academy of Sciences. 103(17). 6659–6664. 640 indexed citations breakdown →
15.
Mossman, Sally, Andrew J. Watson, Michael Robertson, et al.. (2004). Protective Immunity to SIV Challenge Elicited by Vaccination of Macaques with Multigenic DNA Vaccines Producing Virus-Like Particles. AIDS Research and Human Retroviruses. 20(4). 425–434. 19 indexed citations
16.
Topp, Max S., Stanley R. Riddell, Yoshiki Akatsuka, et al.. (2003). Restoration of CD28 Expression in CD28− CD8 + Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production. The Journal of Experimental Medicine. 198(6). 947–955. 109 indexed citations
17.
Lewinsohn, Deborah A., Deborah A. Lewinsohn, David Lewinsohn, et al.. (2002). HIV-1 Vpr Does Not Inhibit CTL-Mediated Apoptosis of HIV-1 Infected Cells. Virology. 294(1). 13–21. 10 indexed citations
18.
Mulvania, Thera, John B. Lynch, Michael Robertson, et al.. (1999). Antigen‐specific cytokine responses in vaccinated Macaca nemestrina. Journal of Medical Primatology. 28(4-5). 181–189. 2 indexed citations
19.
Kent, Stephen J., Virginia Stallard, Lawrence Corey, et al.. (1994). Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses. AIDS Research and Human Retroviruses. 10(5). 551–560. 9 indexed citations
20.
Hoffman, Mark A., et al.. (1994). HIV-Infected Macrophages as Efficient Stimulator Cells for Detection of Cytotoxic T Cell Responses to HIV in Seronegative and Seropositive Vaccine Recipients. AIDS Research and Human Retroviruses. 10(5). 541–549. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerold Schuler Breakdown of academic impact, for papers by James L. Riley Breakdown of academic impact, for papers by Nina Bhardwaj Breakdown of academic impact, for papers by Cornelis J.M. Melief Breakdown of academic impact, for papers by Pedro Romero Breakdown of academic impact, for papers by Stanley R. Riddell Breakdown of academic impact, for papers by Jan W. Drijfhout Breakdown of academic impact, for papers by Douglas T. Fearon Breakdown of academic impact, for papers by Eli Gilboa Breakdown of academic impact, for papers by Esteban Celis
Rankless by CCL
2026